Clinical trial results are critical for biotech companies like Zai Lab, as they can significantly affect the company's product pipeline's credibility and future revenue potential. The publication in a reputable journal such as The New England Journal of Medicine is likely to be viewed positively by investors and could lead to an increase in stock price, especially if the market perceives the drug as having a high potential for successful commercialization.